Memorial Sloan Kettering Cancer Center
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Inclusion Criteria: * Age 18 years or older * ECOG performance status 0-1 * Endometrial cancer: all histologies (submission of pathology report is required for all patients who underwent surgery outside of MSK) * MMR-D or MSI-H or POLE-mutated (submission of report\[s\] required for. patients who underwent testing outside of MSK POLE-mutated endometrial cancers will be included regardless of MMR/MSI status and limited to up to 3 patients per group. * Patients with hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2) will be included * POLE-mutated endometrial cancers will be…
To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.